ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.23
-0.16 (-2.97%)
At close: Sep 9, 2026, 4:00 PM EDT
5.24
+0.01 (0.19%)
Pre-market: Sep 10, 2026, 8:33 AM EDT
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, ARS Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.25. The average 1-year stock price forecast is 344.55% higher than the current stock price, while the lowest is $17 (+225.05%) and the highest is $30 (+473.61%).
Price Target: $23.25 (+344.55%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 5 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $18 → $15 | Buy | Maintains | $18 → $15 | +186.81% | Sep 8, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +473.61% | Aug 14, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 14, 2026 |
| Northland Securities | Northland Securities | Buy Maintains $25 | Buy | Maintains | $25 | +378.01% | Apr 15, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $30 | Buy | Reiterates | $30 | +473.61% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
129.91M
from 84.28M
Increased by 54.14%
Revenue Next Year
190.61M
from 129.91M
Increased by 46.73%
EPS This Year
-1.87
from -1.74
EPS Next Year
-0.90
from -1.87
EPS and Forward PE are based on non-GAAP adjusted numbers.